Nothing Special   »   [go: up one dir, main page]

GB2591194B - Modulation of gene expression and screening for deregulated protein expression - Google Patents

Modulation of gene expression and screening for deregulated protein expression Download PDF

Info

Publication number
GB2591194B
GB2591194B GB2103433.5A GB202103433A GB2591194B GB 2591194 B GB2591194 B GB 2591194B GB 202103433 A GB202103433 A GB 202103433A GB 2591194 B GB2591194 B GB 2591194B
Authority
GB
United Kingdom
Prior art keywords
screening
modulation
expression
gene expression
deregulated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2103433.5A
Other versions
GB202103433D0 (en
GB2591194A (en
Inventor
Vorechovsky Igor
Kralovicova Jana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Priority to GB2103433.5A priority Critical patent/GB2591194B/en
Publication of GB202103433D0 publication Critical patent/GB202103433D0/en
Publication of GB2591194A publication Critical patent/GB2591194A/en
Application granted granted Critical
Publication of GB2591194B publication Critical patent/GB2591194B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB2103433.5A 2015-10-09 2015-10-09 Modulation of gene expression and screening for deregulated protein expression Active GB2591194B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2103433.5A GB2591194B (en) 2015-10-09 2015-10-09 Modulation of gene expression and screening for deregulated protein expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1517937.7A GB2546719B (en) 2015-10-09 2015-10-09 Modulation of gene expression and screening for deregulated protein expression
GB2103433.5A GB2591194B (en) 2015-10-09 2015-10-09 Modulation of gene expression and screening for deregulated protein expression

Publications (3)

Publication Number Publication Date
GB202103433D0 GB202103433D0 (en) 2021-04-28
GB2591194A GB2591194A (en) 2021-07-21
GB2591194B true GB2591194B (en) 2021-10-13

Family

ID=55130855

Family Applications (2)

Application Number Title Priority Date Filing Date
GB2103433.5A Active GB2591194B (en) 2015-10-09 2015-10-09 Modulation of gene expression and screening for deregulated protein expression
GB1517937.7A Active GB2546719B (en) 2015-10-09 2015-10-09 Modulation of gene expression and screening for deregulated protein expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1517937.7A Active GB2546719B (en) 2015-10-09 2015-10-09 Modulation of gene expression and screening for deregulated protein expression

Country Status (1)

Country Link
GB (2) GB2591194B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (en) 2014-10-03 2022-07-01 冷泉港实验室 Targeted increase in nuclear gene export
KR20220105174A (en) 2015-10-09 2022-07-26 유니버시티 오브 사우스앰톤 Modulation of gene expression and screening for deregulated protein expression
GB2559100A (en) * 2016-08-31 2018-08-01 Univ Southampton Modulation of gene expression and screening for deregulated protein expression
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
FI3673080T3 (en) 2017-08-25 2023-11-23 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
MX2020011695A (en) 2018-05-04 2021-02-26 Stoke Therapeutics Inc Methods and compositions for treatment of cholesteryl ester storage disease.
MX2022014151A (en) 2020-05-11 2022-11-30 Stoke Therapeutics Inc Opa1 antisense oligomers for treatment of conditions and diseases.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047772A2 (en) * 1996-06-13 1997-12-18 The Regents Of The University Of California Ataxia-telangiectasia: mutations in the atm gene
WO2001007660A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Methods for detection of ataxia telangiectasia mutations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770372A (en) * 1996-11-20 1998-06-23 Virginia Mason Research Center Detection of mutations in the human ATM gene
CA2273051A1 (en) * 1996-12-03 1998-06-11 Prasanna Athma Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
WO2009151698A1 (en) * 2008-03-14 2009-12-17 The Regents Of The University Of California Rapid assay for detecting ataxia-telangiectasia homozygotes and heterozygotes
US20090270270A1 (en) * 2008-04-28 2009-10-29 Centre Rene Huguenin Method for detecting intragenic large rearrangements
WO2016055829A1 (en) * 2014-10-06 2016-04-14 Mehdipour Parvin Predisposing, preventive, predictive cancer marker kit (3pcm)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047772A2 (en) * 1996-06-13 1997-12-18 The Regents Of The University Of California Ataxia-telangiectasia: mutations in the atm gene
WO2001007660A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Methods for detection of ataxia telangiectasia mutations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature Scientific Reports, Vol 6, 2016, J Kralovicova et al, "Exon-centric regulation of ATM expression is population ..." 18741 *

Also Published As

Publication number Publication date
GB202103433D0 (en) 2021-04-28
GB201517937D0 (en) 2015-11-25
GB2591194A (en) 2021-07-21
GB2546719B (en) 2021-07-14
GB2546719A (en) 2017-08-02

Similar Documents

Publication Publication Date Title
IL258528A (en) Modulation of gene expression and screening for deregulated protein expression
ZA202004919B (en) Anti-tigit antigen-binding proteins and methods of use thereof
HK1249058A1 (en) Compounds and methods for the enhanced degradation of targeted proteins
SG10202112024PA (en) Chimeric proteins and methods of immunotherapy
GB2591194B (en) Modulation of gene expression and screening for deregulated protein expression
EP3218483A4 (en) Compounds and methods for the modulation of proteins
IL252837B (en) Fcrn antibodies and methods of use thereof
HK1254743A1 (en) Novel anti-claudin antibodies and methods of use
HK1254289A1 (en) Methods and antibodies for modulation of immunoresponse
EP3240799A4 (en) S-alkylated hepcidin peptides and methods of making and using thereof
HK1248122A1 (en) Anti-met antibodies and methods of use thereof
IL257170B (en) Stable proteins and methods for designing same
EP3268477A4 (en) Structure based methods for modification of pip-72 polypeptides and pip-72 polypeptides derived therefrom
HK1255456A1 (en) Expression of fc-containing proteins
EP3227681A4 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
GB201506440D0 (en) Riboswitch-controlled screening and selection of desired biocatalysts
EP3535403A4 (en) Modulation of protein accumulation and uses therefor
GB201705121D0 (en) Modulation of gene expression
GB201522618D0 (en) Methods of screening
GB201614744D0 (en) Modulation of gene expression and screening for deregulated protein expression
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
AU2016904541A0 (en) Modulation of protein accumulation and uses therefor
GB201509021D0 (en) Methods of screening
GB201504021D0 (en) Detection of one or more tissue derived aggretated proteins

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40055833

Country of ref document: HK